Thanks, didn't know CHMP rulings have a leaky history. I concur that selling the indication isn't going to be easy -- given the way American oncologists are incentivised (i.e. tilting the market in favor of infusion therapies), I'm somewhat surprised Tarceva has done as well as it has -- but it has to be a net positive, even if a small one. Any thoughts on other aspects of the situation? I am now reading that OSI claims to be in talks with other parties:
"To help nudge things along, OSI said yesterday that it is in talks with other potential buyers, including some unnamed Big Pharma players."
The only thing I saw in OSI's PR from the 16th was that it had authorized the board to talk to other parties, which is not quite the same thing as actually being in talks with Big Pharmas. Meanwhile, a few shareholders are suing the board in an effort to prevent it from using the poison pill. I guess $52.00 sooner versus something else later is enough, if you're underfunded pension fund . . . Roche has been bandied about as a potential white knight for obvious reasons.
Market Data 
Markets 
AI
